Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) FCF Margin (2021 - 2024)

Historic FCF Margin for Allogene Therapeutics (ALLO) over the last 4 years, with Q1 2024 value amounting to 254122.73%.

  • Allogene Therapeutics' FCF Margin fell 285427300.0% to 254122.73% in Q1 2024 from the same period last year, while for Dec 2024 it was 913609.09%, marking a year-over-year decrease of 6617680400.0%. This contributed to the annual value of 913609.09% for FY2024, which is 6617680400.0% down from last year.
  • Allogene Therapeutics' FCF Margin amounted to 254122.73% in Q1 2024, which was down 285427300.0% from 256609.52% recorded in Q4 2023.
  • In the past 5 years, Allogene Therapeutics' FCF Margin registered a high of 61.03% during Q4 2021, and its lowest value of 282477.27% during Q2 2023.
  • For the 4-year period, Allogene Therapeutics' FCF Margin averaged around 166409.53%, with its median value being 179843.59% (2022).
  • Examining YoY changes over the last 5 years, Allogene Therapeutics' FCF Margin showed a top increase of 455666200bps in 2022 and a maximum decrease of 2000000000bps in 2022.
  • Allogene Therapeutics' FCF Margin (Quarter) stood at 61.03% in 2021, then tumbled by -401877bps to 245338.46% in 2022, then decreased by -5bps to 256609.52% in 2023, then grew by 1bps to 254122.73% in 2024.
  • Its FCF Margin stands at 254122.73% for Q1 2024, versus 256609.52% for Q4 2023 and 252463.64% for Q3 2023.